Keywords
activated factor VII–anti-thrombin complex -
APOC3 gene polymorphism - apolipoprotein C-III - coagulation - plasma lipids
Introduction
Plasma lipids play a crucial role in the pathogenesis of cardiovascular disease (CVD).[1] Lipoproteins are the main actors of a finely tuned system to transport lipids through
the whole body according to its metabolic needs. Lipoproteins have a mono-layer phospholipid
and cholesterol outer shell and heterogeneous lipid core. Apolipoproteins are embedded
in the outer shell, both stabilizing the structure and determining their functional
characteristics.
Alterations in levels of plasma lipids are well recognized among the most important
risk factors of CVD, and lipid-lowering drugs are among the most widely used drugs
in Western world.[2]
[3] The increase of cardiovascular risk due to alterations in plasma lipids concentration
is usually attributed to atherosclerosis-related processes. However, lipoproteins
are endowed with various biological properties and have been also demonstrated to
influence the coagulation pathway.
Coagulation needs lipids and the cascade is greatly accelerated by lipid binding.[4] Several coagulation factors are equipped with specialized membrane phospholipid-binding
domains, which are essential for proper clot formation.[4] Tissue factor (TF), whose interaction with activated factor VII (FVIIa) starts the
coagulation cascade, is not only an integral membrane protein but its ectodomain is
also involved in phospholipid interactions which enhance FVIIa activity.[5] Thrombin generation is dependent on the assembly of the pro-thrombinase complex
on a phospholipid surface.[6] In clinical studies, plasma levels of both cholesterol and triglycerides have been
directly correlated with plasma levels of coagulation factors, especially with the
vitamin K-dependent ones,[7] as well as with thrombin generation.[8] Experimental data suggest that all plasma lipoproteins stimulate coagulation cascade,
with triglyceride-rich lipoproteins (TRLs) being apparently the most efficient.[9]
[10]
Activated FVII–anti-thrombin (FVIIa-AT) complex is an indirect marker of intravascular
exposure of TF and, consequently, of activation of the extrinsic coagulation pathway.
While still incompletely understood, the transition from inactive (encrypted) to active
(decrypted) form of TF and its binding and activation of FVII is the key initiator
of coagulation cascade.[11]
[12]
[13] Both AT and TF pathway inhibitor (TFPI) acts as inhibitors of the TF-FVIIa pathway.
TFPI forms with TF, FVIIa and activated coagulation FXa, a stable quaternary complex
which remains bound to the cellular surface. On the other hand, once the TF-FVIIa-AT
complex is formed, FVIIa loses affinity for TF and FVIIa-AT is released and accumulates
in the plasma where it can be measured.[14] Therefore, FVIIa-AT plasma levels indirectly reflect TF-FVIIa interaction and have
been suggested as a biomarker of pro-thrombotic diathesis.[15]
[16]
[17] A slight increase in FVIIa-AT plasma concentration was observed in subjects with
previous arterial and/or venous thrombosis,[15] as well as in survivors after myocardial infarction.[16] In the setting of primary prevention of coronary artery disease (CAD) within the
Stockholm study of 60-year-old individuals, FVIIa-AT had no predictive value,[16] while in the secondary prevention setting within the Verona Heart Study (VHS) population,
high FVIIa-AT levels predicted total and cardiovascular mortality in patients with
clinically stable CAD.[17] This suggests that FVIIa-AT levels may be more related with later thrombotic complications
of CAD, rather than with the early development of atherosclerotic plaques. Accordingly,
a recent analysis in participants to the large Cardiovascular Health Study has shown
that high FVIIa-AT levels may reflect an increased risk of mortality.[18]
In our previous study, high-density lipoprotein (HDL) cholesterol and triglycerides
were independent predictors of FVIIa-AT variability, even after adjustment for FVIIa
levels,[17] thus addressing the interest on the complex and still controversial link between
plasma lipids and coagulation.
On the basis of such premises, to investigate more in depth the relationship between
FVIIa-AT and plasma lipids, we performed a new series of analyses evaluating a broad
apolipoprotein profile, including apolipoprotein A-I (ApoA-I), B (ApoB), C-III (ApoC-III)
and E (ApoE), in the original VHS population cohort previously assessed for FVIIa-AT.
Materials and Methods
Study Population
This study was performed within the framework of the VHS, a regional survey aimed
to look for new CAD risk factors in subjects with angiographic documentation of their
coronary vessels.[19] Briefly, all the subjects in the VHS are required to have no history of any acute
illness in the month preceding the enrolment. CAD patients with acute coronary syndrome
were excluded from this study. Subjects with severe renal failure (estimated glomerular
filtration rate [eGFR] < 30 mL/min) and those with severe hepatic impairment (clinically
defined diagnosis of liver cirrhosis) were also excluded from this study. The study
design is summarized in [Supplementary Fig. S1], available in the online version. Within the original study population not taking
any anticoagulant drugs who have been assessed for FVIIa-AT levels,[17] we selected the 666 subjects for whom plasma samples for apolipoprotein assays were
available (75.4% males, mean age: 61.1 ± 10.9 years). One hundred and thirty-one subjects
having completely normal coronary arteries (undergoing coronary angiography for reasons
other than CAD, mainly valvular heart disease) were used as controls (CAD-free group).
These subjects had also no history, or clinical or instrumental evidence of atherosclerosis
outside the coronary bed. Five hundred and thirty-five subjects had angiographically
proven CAD (CAD group), with at least one of the major epicardial coronary arteries
(left anterior descending, circumflex and right) affected with ≥ 1 significant stenosis
(≥ 50% lumen reduction). All the CAD patients were newly diagnosed at time of enrolment,
that is, at time of coronary angiography. The angiograms were assessed blind by two
cardiologists who were unaware that the patients were to be included in this study.
All participants came from the same geographical area of northern Italy. At the time
of blood sampling, a complete clinical history was collected, as well as data about
drug therapies. The study complies with the Declaration of Helsinki and was approved
by the Ethic Committee of our institution (Azienda Ospedaliera Universitaria Integrata,
Verona, Italy). A written informed consent was obtained from all the participants.
Biochemical Analysis
Samples of venous blood were drawn from each subject, after an overnight fast, at
the time of enrolment before coronary angiography. Serum lipids, as well as other
CAD risk factors, including high-sensitivity C-reactive protein (hs-CRP), were determined
as previously described.[17]
[19] Very low-density lipoprotein (VLDL) cholesterol was calculated by subtracting from
total cholesterol the concentration of HDL and low-density lipoprotein (LDL) cholesterol.
The four variables version of the Modification of Diet in Renal Disease equation was
used to estimate the GFR from serum creatinine levels.[20]
Apolipoprotein Assays
ApoA-I, ApoB and ApoE were measured by commercially available nephelometric immunoassays,
as previously described.[21] ApoC-III concentration was measured using an automated turbidimetric immunoassay
(Wako Pure Chemical Industries). Intra-assay coefficients of variation (CVs) were
1.84, 2.02 and 1.98% on three pools of control sera with low, medium and high concentrations
of ApoCIII, respectively; inter-assay CVs were 4.4, 3.4 and 2.29% for low, medium
and high concentration, respectively.[22]
[23]
FVIIa-AT and FVIIa Assays
The concentration of FVIIa-AT was measured by enzyme-linked immunosorbent assay (Asserachrom
VIIa-AT, Diagnostica Stago, Asnieres, France) on frozen citrate plasma samples, never
thawed before this study. Venous blood samples collected at the time of enrolment
were centrifuged, stored in 0.5 mL aliquots and frozen at –80°C within 1 hour after
sample collection. Plasma samples were thawed in a water bath at 37°C for 5 minutes
before FVIIa-AT assay. All testing was performed in duplicate. The intra- and inter-assay
CVs were < 5%.[17]
FVIIa was assessed with a kit utilizing a soluble recombinant truncated TF that is
selectively deficient in promoting FVII activation but retains recombinant FVIIa (rFVIIa)
co-factor function, thus allowing direct quantification of FVIIa in plasma (Staclot
VIIa-rTF, Diagnostica Stago). Values were expressed in milliunits per millilitre,
30 such units being equivalent to 1 ng of FVIIa. The standard was a rFVIIa supplied
with the kit. The intra- and inter-assay CVs were 7.8 and 6.4%, respectively.[21] Plasma samples for FVIIa assay were available for 291 subjects (43.7%).
Single Nucleotide Polymorphisms and Genotyping
Genomic deoxyribonucleic acid (DNA) was prepared from whole blood samples by phenol-chloroform
extraction.
The rs964184 C/G polymorphism is located on chromosome 11q23.3, tagging ZNF259, APOA5-APOA4-APOC3-APOA1 gene region. Genome-wide association studies (GWAS) proved that the G allele is associated
with high levels of triglycerides and LDL cholesterol, low levels of HDL cholesterol
and an increased risk of CAD.[24]
[25]
[26] rs964184 single nucleotide polymorphism (SNP) was genotyped using Taqman platform.
DNA samples for rs964184 analysis were available for 540 subjects (81.0%).
Polymorphisms in the APOE gene, rs429358 (Cys112Arg) and rs7412 (Arg158Cys), encode three common alleles, ε2
(Cys122 and Cys158), ε3 (Cys112 and Arg158) and ε4 (Arg112 and Arg158), which combine
to form six genotypes, ε2/ε2, ε2/ε3, ε2/ε4, ε3/ε3, ε3/ε4 and ε4/ε4. APOE ε2/ε3/ε4 polymorphisms are among the most investigated gene variants being a key
regulator of lipoprotein metabolism.[27]
[28] APOE polymorphisms were genotyped according to a previously described multi-locus assay[29] and data were available for 495 subjects (74.3%).
Statistics
All calculations were performed using the IBM SPSS 20.0 (IBM Inc., Armonk, New York,
United States) statistical package.
Distributions of continuous variables in groups were expressed as means ± standard
deviations. Skewed variables, including FVIIa-AT, FVIIa, hs-CRP, VLDL cholesterol,
triglyceride, ApoC-III and ApoE, were logarithmically transformed and then geometric
means with 95% confidence interval were reported. Quantitative data were assessed
using the Student's t-test or by analysis of variance, with polynomial contrast for linear trend when indicated.
Qualitative data were analysed with the chi-square test and with chi-square for linear
trend analysis when indicated. The frequencies of the genotypes associated with each
of the assessed polymorphisms were compared by using the chi-square test with the
values predicted on the basis of the Hardy–Weinberg equilibrium.
Significant associations between FVIIa-AT plasma concentration and lipid parameters
(i.e. traditional plasma lipids and apolipoproteins) were evaluated at first by Pearson's
correlation coefficient (R) in the whole study population, as well as in either males or females and in either
CAD or CAD-free sub-groups. To assess the independent predictors of FVIIa-AT levels,
all the variables showing an association with the FVIIa-AT complex at univariate analysis
were included in an adjusted regression model. Further adjustments were performed
including in the regression models sex, age, body mass index (BMI), eGFR, smoking
status, CAD diagnosis, lipid-lowering therapy and FVIIa. Taking into account the low
number of subjects for whom FVIIa levels were available (n = 291), data of FVIIa were added in a separate adjusted regression model.
A value of p < 0.05 was considered statistically significant.
Results
Clinical and laboratory characteristics of the study population are reported in [Table 1]. As previously observed,[17] no difference in FVIIa-AT levels was found between CAD and CAD-free subjects ([Table 1]). As regards plasma lipids and apolipoproteins, HDL cholesterol and ApoA-I were
lower while triglyceride and ApoC-III were higher in patients with CAD than in CAD-free
subjects, although with a substantial overlap in plasma levels between cases and controls
([Table 1]). In the whole study population, several significant direct correlations were found
between FVIIa-AT and lipid variables. Total and HDL cholesterol, triglycerides, ApoA-I,
ApoC-III and ApoE correlated directly with FVIIa-AT levels ([Table 2]). The association with ApoC-III was the strongest with high statistical significance
(R = 0.235, p = 7.7 × 10−10; [Fig. 1]) and was the only confirmed association in all the sub-group analyses (i.e. males
and females, CAD and CAD-free; [Table 2]). Including total and HDL cholesterol, triglycerides, ApoA-I, ApoC-III and ApoE
(i.e. the variables showing an association with the FVIIa-AT complex at univariate
analysis) in a regression model for FVIIa-AT variability, only ApoC-III remained associated
with FVIIa-AT ([Table 3]). Such association was confirmed after adjustment for sex, age, CAD diagnosis, BMI,
eGFR, smoking status and lipid-lowering therapies (standardized β-coefficient = 0.158,
p = 0.011; [Table 3]). Taking into account that ApoC-III levels correlated with all plasma lipid parameters
([Supplementary Table S1], available in the online version), a further regression model including all plasma
lipids and apolipoproteins was performed and found that ApoC-III remained associated
with FVIIa-AT also by this analysis (standardized β-coefficient = 0.209, p = 0.004). The strong correlation between ApoC-III and FVIIa-AT was confirmed in the
sub-group of subjects not taking lipid-lowering therapies at enrolment (n = 497; R = 0.251, p = 1.3 × 10−8), even in full-adjusted regression model (standardized β-coefficient = 0.183, p = 0.007). Considering the potential influence of smoking status on both TRLs metabolism
and TF-FVIIa pathway, analyses according to smoking status were also performed. The
strong direct correlation between ApoC-III and FVIIa-AT plasma levels was confirmed
in both smokers (R = 0.221, p = 7.0 × 10−6) and non-smokers (R = 0.269, p = 3.6 × 10−5).
Table 1
Clinical and laboratory characteristics of the study population, considered as a whole
or divided in sub-groups with or without coronary artery disease (CAD)
|
Total population
(n = 666)
|
CAD-free
(n = 131)
|
CAD
(n = 535)
|
p-Value[a]
|
|
Age (y)
|
61.1 ± 10.9
|
60.4 ± 11.9
|
61.3 ± 10.7
|
NS
|
|
Males (%)
|
75.4
|
69.5
|
76.8
|
NS
|
|
BMI (kg/m2)
|
26.6 ± 3.8
|
26.0 ± 3.6
|
26.8 ± 3.8
|
0.042
|
|
Diabetes (%)
|
19.0
|
8.1
|
21.6
|
0.001
|
|
Hypertension (%)
|
64.1
|
45.3
|
68.7
|
< 0.001
|
|
Smoke (%)
|
63.8
|
43.7
|
68.5
|
< 0.001
|
|
eGFR (mL/min)[b]
|
73.7 ± 19.9
|
74.2 ± 21.0
|
73.5 ± 19.7
|
NS
|
|
hs-CRP (mg/L)
|
4.23
(3.78–4.73)
|
2.33
(1.84–2.94)
|
4.98
(4.40–5.64)
|
< 0.001
|
|
Lipid-lowering therapy (%)
|
25.4
|
8.4
|
29.5
|
< 0.001
|
|
Total cholesterol (mmol/L)
|
5.18 ± 1.10
|
5.21 ± 1.04
|
5.17 ± 1.11
|
NS
|
|
LDL cholesterol (mmol/L)
|
3.41 ± 0.94
|
3.34 ± 0.95
|
3.42 ± 0.93
|
NS
|
|
HDL cholesterol (mmol/L)
|
1.20 ± 0.33
|
1.38 ± 0.41
|
1.16 ± 0.29
|
< 0.001
|
|
VLDL cholesterol (mmol/L)
|
0.67
(0.65–0.69)
|
0.54
(0.50–0.58)
|
0.71
(0.68–0.73)
|
< 0.001
|
|
Triglyceride (mmol/L)
|
1.58
(1.53–1.64)
|
1.28
(1.19–1.36)
|
1.67
(1.61–1.73)
|
< 0.001
|
|
ApoA-I (g/L)
|
1.28 ± 0.26
|
1.36 ± 0.30
|
1.26 ± 0.25
|
< 0.001
|
|
ApoB (g/L)
|
1.04 ± 0.28
|
1.01 ± 0.25
|
1.05 ± 0.28
|
NS
|
|
ApoC-III (mg/dL)
|
10.5
(10.2–10.8)
|
9.9
(9.3–10.5)
|
10.6
(10.3–11.0)
|
0.038
|
|
ApoE (g/L)
|
0.037
(0.035–0.038)
|
0.038
(0.035–0.039)
|
0.036
(0.035–0.037)
|
NS
|
|
FVIIa-AT (pM)
|
84.7
(81.5–88.0)
|
85.2
(77.4–93.9)
|
84.5
(81.1–88.1)
|
NS
|
|
FVIIa (mU/mL)[c]
|
46.9
(43.8–50.1)
|
46.1
(40.0–53.0)
|
47.2
(43.7–50.9)
|
NS
|
Abbreviations: Apo, apolipoprotein; BMI, body mass index; eGFR, estimated glomerular
filtration rate; FVIIa-AT, factor VII–anti-thrombin; HDL, high-density lipoprotein;
hs-CRP, high-sensitivity C-reactive protein; LDL, low-density lipoprotein; MDRD, Modification
of Diet in Renal Disease; NS, not significant; VLDL, very low-density lipoprotein.
a By t-test or chi-square test, when appropriate.
b By MDRD formula.
c Data were available for 291 subjects (76 CAD-free and 215 CAD).
Table 2
Correlations between activated factor VII–anti-thrombin complex (FVIIa-AT) and plasma
lipids and apolipoproteins, in the whole study population and in the different sub-groups
on the basis of coronary artery disease (CAD) diagnosis and gender
|
Whole study
population
(n = 666)
|
CAD-free
(n = 131)
|
CAD
(n = 535)
|
Males
(n = 502)
|
Females
(n = 164)
|
|
R
|
p
|
R
|
p
|
R
|
p
|
R
|
p
|
R
|
p
|
|
Total cholesterol
|
0.081
|
0.041
|
0.234
|
0.008
|
0.040
|
NS
|
0.098
|
0.030
|
-0.006
|
NS
|
|
LDL cholesterol
|
0.040
|
NS
|
0.161
|
NS
|
0.008
|
NS
|
0.050
|
NS
|
0.028
|
NS
|
|
HDL cholesterol
|
0.117
|
0.005
|
0.170
|
NS
|
0.091
|
0.049
|
0.101
|
0.034
|
0.035
|
NS
|
|
VLDL cholesterol
|
0.058
|
NS
|
0.145
|
NS
|
0.042
|
NS
|
0.045
|
NS
|
0.122
|
NS
|
|
Triglyceride
|
0.110
|
0.005
|
0.218
|
0.014
|
0.091
|
0.038
|
0.120
|
0.008
|
0.121
|
NS
|
|
ApoA-I
|
0.158
|
< 0.001
|
0.132
|
NS
|
0.168
|
< 0.001
|
0.183
|
< 0.001
|
0.035
|
NS
|
|
ApoB
|
–0.020
|
NS
|
0.107
|
NS
|
–0.023
|
NS
|
–0.021
|
NS
|
0.009
|
NS
|
|
ApoC-III
|
0.235
|
< 0.001
|
0.336
|
< 0.001
|
0.211
|
< 0.001
|
0.244
|
< 0.001
|
0.187
|
0.016
|
|
ApoE
|
0.125
|
0.001
|
0.090
|
NS
|
0.135
|
0.002
|
0.161
|
< 0.001
|
–0.024
|
NS
|
Abbreviations: Apo, apolipoprotein; HDL, high-density lipoprotein; LDL, low-density
lipoprotein; NS, not significant; VLDL, very low-density lipoprotein.
Note: Significant correlations are reported in bold.
Table 3
Linear regression analysis for variability of activated factor VII–anti-thrombin complex
(FVIIa-AT) plasma levels
|
Model 1
|
Model 2
|
|
Standardized
β-coefficient
|
p-Value
|
Standardized
β-coefficient
|
p-Value
|
|
Total cholesterol
|
–0.087
|
0.076
|
–0.060
|
0.264
|
|
HDL cholesterol
|
0.108
|
0.113
|
0.065
|
0.395
|
|
Triglyceride
|
0.048
|
0.426
|
0.047
|
0.465
|
|
ApoA-I
|
0.053
|
0.422
|
0.114
|
0.108
|
|
ApoC-III
|
0.200
|
0.001
|
0.158
|
0.011
|
|
ApoE
|
0.066
|
0.135
|
0.028
|
0.550
|
Abbreviations: Apo, apolipoprotein; BMI, body mass index; CAD, coronary artery disease;
eGFR, estimated glomerular filtration rate; HDL, high-density lipoprotein.
Note: FVIIa-AT was considered as dependent variable, while all plasma lipids and apolipoproteins
showing a significant correlation at univariate analysis were included as independent
variables (Model 1). The regression model was then adjusted for sex, age, CAD diagnosis,
BMI, renal function and lipid-lowering therapies at enrolment (Model 2). Significant
associations are reported in bold.
Model 1: Total cholesterol, HDL cholesterol, triglyceride, ApoA-I, ApoC-III and ApoE
as independent variables.
Model 2: Model 1 plus sex, age, CAD diagnosis, BMI, eGFR, smoking status and lipid-lowering
therapies at enrolment as independent variables.
Fig. 1 Correlation between plasma concentrations of activated factor VII–anti-thrombin complex
(FVIIa-AT) and apolipoprotein C-III (ApoC-III) in the whole study population. *Pearson's
correlation test.
Within the sub-group of subjects with available data of FVIIa (n = 291), ApoC-III plasma concentration correlated directly also with FVIIa levels
(R = 0.291, p = 4.4 × 10−7). In an adjusted regression model, both ApoC-III (standardized β-coefficient = 0.178,
p = 0.001) and FVIIa (standardized β-coefficient = 0.479, p < 0.001) remained significant predictors of FVIIa-AT variability ([Supplementary Table S2], available in the online version).
Stratifying the study population on the basis of ApoC-III plasma concentration, FVIIa-AT
levels increased progressively from the lowest to the highest quartile ([Fig. 2] and [Supplementary Table S3], available in the online version) and such trend was confirmed in all the main sub-group
analyses ([Fig. 2]), including those in smoker and non-smoker sub-populations ([Supplementary Fig. S2], available in the online version). As expected, subjects with high ApoC-III levels
had an unfavourable lipid profile ([Supplementary Table S3], available in the online version).
Fig. 2 Activated factor VII–anti-thrombin complex (FVIIa-AT) levels according to apolipoprotein
C-III (ApoC-III) plasma concentration quartiles in the whole study population, in
subjects with or without coronary artery disease (CAD) and in male and female sub-groups.
*Analysis of variance (ANOVA) with polynomial contrasts for linear trend.
Considering the strong direct correlation of ApoC-III with triglycerides (R = 0.559, p = 2.6 × 10−54) and ApoE (R = 0.290, p = 2.2 × 10−14), which are all parameters characterizing TRLs, we performed a further analysis stratifying
the study population on the basis of triglycerides, ApoC-III and ApoE median values.
All the sub-groups having ApoC-III above the median plasma concentration had increased
levels of FVII-AT rather than those with low ApoC-III, independent of both triglycerides
and ApoE plasma concentration ([Fig. 3]).
Fig. 3 Activated factor VII–anti-thrombin complex (FVIIa-AT) levels according to triglyceride
(TG), apolipoprotein C-III (ApoC-III) and apolipoprotein E (ApoE) plasma concentrations.**The
whole study population has been stratified according the median levels of TG (1.56
mmol/L), ApoC-III (10.4 mg/dL) and ApoE (0.037 g/L). Therefore, eight sub-groups were
obtained, each characterized by a combination of high or low plasma concentration
of TG, ApoC-III and ApoE. The horizontal dotted line indicates the median level of
FVIIa-AT in the whole study population (78.5 pM). †Analysis of variance (ANOVA) with
Tukey's post hoc comparison.
We investigated also genetic components supporting the association between ApoC-III
and FVII-AT. Within the study population, 540 subjects were genotyped for rs964184
polymorphism, which tags APOA5-APOA4-APOC3-APOA1 locus and has been linked by GWAS with both dyslipidaemia and CAD. The genotype distribution
was consistent with the Hardy–Weinberg equilibrium. As expected, the carriers of the
minor allele (G) were more represented among CAD and had an unfavourable lipid profile
([Table 4]). While no significant difference was found for ApoA-I, ApoB and ApoE, the carriers
of the G allele had higher ApoC-III plasma concentration and also higher FVIIa-AT
levels ([Fig. 4]). Within the genotyped population, data on FVIIa were available for 253 subjects
and G allele carriers had increased levels of FVIIa ([Table 4]). On the other hand, APOE ε2/ε3/ε4 genotypes were not related with FVIIa-AT levels, while—as expected—the associations
with ApoE, triglycerides and VLDL cholesterol were confirmed ([Supplementary Table S4], available in the online version).
Fig. 4 Plasma concentrations of apolipoprotein C-III (ApoC-III) and activated factor VII–anti-thrombin
complex (FVIIa-AT) according to rs964184 genotypes.
Table 4
Clinical and laboratory characteristics, including plasma lipids and activated factor
VII–anti-thrombin complex (FVIIa-AT) levels, according rs964184 genotype (data available
for 540 subjects)
|
rs964184 polymorphism
|
p-Value[a]
|
|
CC
(n = 400)
|
CG
(n = 127)
|
GG
(n = 13)
|
|
Age (y)
|
60.5 ± 11.2
|
62.1 ± 9.5
|
65.0 ± 10.0
|
NS
|
|
Males (%)
|
76.3
|
76.4
|
76.9
|
NS
|
|
CAD diagnosis (%)
|
80.3
|
86.6
|
92.3
|
0.058
|
|
BMI (kg/m2)
|
26.5 ± 3.7
|
26.9 ± 3.9
|
26.5 ± 5.3
|
NS
|
|
Lipid-lowering therapy (%)
|
24.8
|
28.3
|
23.1
|
NS
|
|
Total cholesterol (mmol/L)
|
5.19 ± 0.98
|
5.24 ± 1.35
|
5.25 ± 1.02
|
NS
|
|
LDL cholesterol (mmol/L)
|
3.34 ± 0.85
|
3.69 ± 1.10
|
3.54 ± 0.79
|
0.007
|
|
HDL cholesterol (mmol/L)
|
1.20 ± 0.33
|
1.17 ± 0.27
|
1.15 ± 0.20
|
NS
|
|
VLDL cholesterol (mmol/L)
|
0.66
(0.63–0.69)
|
0.71
(0.66–0.76)
|
0.89
(0.72–1.11)
|
0.011
|
|
Triglyceride (mmol/L)
|
1.57
(1.50–1.64)
|
1.69
(1.57–1.82)
|
2.18
(1.85–2.57)
|
0.005
|
|
ApoA-I (g/L)
|
1.26 ± 0.26
|
1.26 ± 0.26
|
1.27 ± 0.22
|
NS
|
|
ApoB (g/L)
|
1.05 ± 0.26
|
1.05 ± 0.32
|
1.02 ± 0.35
|
NS
|
|
ApoC-III (mg/dL)
|
10.5
(10.1–10.8)
|
10.8
(10.1–11.5)
|
13.9
(11.6–16.7)
|
0.033
|
|
ApoE (g/L)
|
0.036
(0.035–0.038)
|
0.036
(0.034–0.038)
|
0.038
(0.028–0.052)
|
NS
|
|
FVIIa-AT (pM)
|
81.4
(77.7–85.4)
|
89.9
(83.0–97.4)
|
97.7
(75.7–126.0)
|
0.018
|
|
FVIIa (mU/mL)[b]
|
43.8
(39.9–48.0)
|
53.4
(45.9–62.1)
|
51.7
(42.0–63.7)
|
0.042
|
Abbreviations: Apo, apolipoprotein; ANOVA, analysis of variance; BMI, body mass index;
CAD, coronary artery disease; HDL, high-density lipoprotein; LDL, low-density lipoprotein;
NS, not significant; VLDL, very low-density lipoprotein.
a By ANOVA with polynomial contrasts for linear trend or chi-square test for linear
trend, when appropriate.
b Data were available for 253 subjects (CC, n = 188; CG, n = 56; GG, n = 7).
Discussion
In this study, we show that (1) ApoC-III has the strongest association with FVIIa-AT
among plasma lipid parameters, and (2) carriers of the minor allele of rs964184 gene
polymorphism, tagging APOC3 locus and known to influence ApoC-III plasma concentration and cardiovascular risk,[24]
[25]
[26] had FVIIa-AT levels higher than non-carriers. Thereby, these results suggest a link
between ApoC-III and the TF-related initiation phase of the blood clotting cascade.
ApoC-III is a crucial player of TRLs metabolism and is recognized as a key determinant
of cardiovascular risk by correlating with an unfavourable lipoprotein metabolism.[30]
[31] ApoC-III, synthesized mainly in the liver, resides mostly on the surface of VLDLs,
but also on LDLs and HDLs, and can reduce the clearance of ApoB lipoproteins from
the circulation by interfering with their binding to hepatic ApoB/ApoE receptors.[32] Moreover, ApoC-III inhibits the action of lipoprotein lipase to hydrolyze lipoprotein
triglycerides. Finally, ApoC-III contributes to the formation of TRLs in liver cells,
stimulating the secretion of VLDL.[32] GWAS have identified polymorphisms tagging APOC3 that strongly associated with both dyslipidaemia and CVD, according with the hypothesis
of an increased cardiovascular risk mediated by TRLs.[24]
[25]
[26] Loss-of-function mutations of the APOC3 gene have been associated with a decreased risk of CVD paving the way to ApoC-III-lowering
therapies as innovative approaches to reduce cardiovascular risk.[33] Volanesorsen—an anti-ApoC-III antisense oligonucleotide—has been demonstrated in
phase II clinical trials to be potentially a new powerful tool for the therapy of
hypertriglyceridaemia.[34] Noteworthy, the mechanisms linking TRLs (including ApoC-III-rich lipoproteins) and
CVD go beyond the traditional view of atherosclerotic plaque development due to lipid
accumulation and may include excessive free fatty acid release and production of pro-inflammatory
cytokines, which in turn could increase TF expression, as well as stimulation of coagulation
factors and impairment of fibrinolysis.[3]
In this article, we add a further tile to the mosaic of pleiotropic effects of ApoC-III,
emphasizing its potential pro-coagulant capability, which has previously been addressed
by our group.[22]
[23] We originally showed that increased ApoC-III concentrations correlated with an amplified
plasma endogenous thrombin generation.[22] Then, we found that high ApoC-III levels were associated with an increase of FII
coagulant activity to an extent comparable with the carriership of the A allele of
F2 20210G > A gene polymorphism.[23] We also observed a direct correlation of ApoC-III plasma concentration with both
FVIIa and FV coagulant activities. Finally, high levels of ApoC-III were related with
an enhanced activated FXa generation.[23]
The results of this study, showing a strong direct correlation between ApoC-III and
FVIIa-AT, appear consistent with earlier findings ([Supplementary Fig. S3], available in the online version). The correlation of ApoC-III with FVIIa-AT suggests
increased intravascular amounts of TF-FVIIa complex in subjects with high ApoC-III
plasma concentrations. An increased exposure of decrypted TF could be hypothesized,
leading to an enhanced FVII activation and consequently to a greater FXa generation.[23] The extrinsic pathway potentiation would be reflected in an amplified common pathway,
resulting into increased FV and FII coagulant activities[23] and thrombin generation.[22]
In our previous work, both triglycerides and HDL cholesterol correlated directly with
FVIIa-AT,[17] but in this analysis such correlations were no longer evident after adjustment for
ApoC-III. ApoC-III is expressed on both TRLs and HDLs and recent data support that
it may not only characterize the harmful effects of TRLs but also may adversely affect
the anti-atherogenic properties of HDL.[35]
[36] This result prompts that ApoC-III may be a key player of pro-coagulant effects associated
to both TRLs and HDLs. Considering all the parameters characterizing TRLs which were
available in our study (i.e. triglyceride, ApoC-III and ApoE), only an elevated ApoC-III
concentration was unvaryingly associated with high FVIIa-AT levels. Our results are
consistent with previous works showing the pro-coagulant properties of VLDL, which
typically express ApoC-III.[9]
[10] Thrombin generation sustained by VLDLs was found to be 19.4-fold greater than that
sustained by HDLs and 11.7-fold greater than that sustained by LDLs.[9]
[10] VLDLs support all the components of the extrinsic coagulation pathway[10] and can both stimulate TF expression and enhance TF-independent FVII activation.[37] VLDLs are functionally characterized by ApoC-III expression. However, it is not
known if ApoC-III might participate in VLDL micro-domains with distinct local lipid
compositions able to support/enhance TF-FVIIa interaction. It may be also speculated
that the rise of FVIIa-AT is secondary to the TRLs-related increase of FVIIa levels,
whose concentration has been found to be the main determinant of FVIIa-AT in plasma.[16] However, in our analysis the association between ApoC-III and FVIIa-AT was independent
of FVIIa, thus suggesting that ApoC-III may influence expression and/or activity of
TF rather than merely FVIIa levels. It is worthy to note that in a recent study high
FVIIa-AT levels were related with post-prandial lipaemia.[38] Since post-prandial lipaemia is characterized by high concentrations of ApoC-III,[39] such observation appears consistent with our findings. Moreover, considering the
rapid change in levels observed within short time intervals (< 6 hours),[38] it could suggest involvement of release/activation processes rather than biosynthesis
of new TF and FVII molecules.
Our hypothesis of a pro-coagulant role of ApoC-III is strengthened by the analysis
of rs964184 polymorphism, which tags the gene cluster containing the APOC3 locus and has been linked by GWAS with both dyslipidaemia and CAD.[24]
[25]
[26] This variant exerts multiple functional effects on the expression of the gene cluster.[40] The higher levels of FVIIa-AT found in carriers of the risk allele G further supports
a link between ApoC-III and extrinsic coagulation pathway. Noteworthy, another key
gene variant in TRLs metabolism, that is, the APOE ε2/ε3/ε4 polymorphism, did not associate with FVIIa-AT levels, consistently with
the analysis of FVIIa-AT on the basis of triglyceride, ApoC-III and ApoE levels ([Fig. 3]). Up to now GWAS have linked approximately 60 genetic loci to CAD.[41] Although coagulation plays a crucial role in CAD pathophysiology, very few of these
GWAS-identified loci have been related with haemostatic processes so far.[42]
[43] The here reported association suggests that one of the SNPs with the strongest association
with CAD identified by GWAS,[25] beyond the effects on lipid metabolism, may influence also blood coagulation.
Our results, supporting a connection between ApoC-III/TRLs and pro-thrombotic diathesis
marked by FVIIa-AT, may have implications for both arterial and venous thrombosis.
As a matter of fact, high levels of FVIIa-AT have been observed in patients with venous
thromboembolism (VTE),[15] and hypertriglyceridaemia has been also related with VTE[44] and lipid-lowering therapies may reduce VTE risk.[45]
It is important to underline some limitations of this work. First, our results may
be intrinsically flawed by the cross-sectional design. Statistical association does
not mean biological causality and no insights on the possible causal mechanisms linking
ApoC-III and coagulation can be inferred. It could be argued that apolipoproteins
could remodel the phospholipid distribution in cellular membranes,[46]
[47] which in turn influences TF-FVIIa activity at the cell surface.[48]
[49]
[50] However, our work does not provide any proof about the molecular mechanisms potentially
linking ApoC-III and TF-FVIIa interaction. It could be not excluded that ApoC-III
plasma levels may merely alter either directly or indirectly the clearance of FVIIa-AT
complex (e.g. by interfering with hepatocyte-related clearance), without any significant
effects on TF-FVIIa interaction. Nonetheless, the present result, consistent with
previous works[22]
[23] demonstrating that high ApoC-III concentrations are associated with an increased
activation of extrinsic and common pathways of coagulation cascade ([Supplementary Fig. S3], available in the online version), suggests a link between ApoC-III and pro-coagulant
diathesis more than an influence on clearance of the inactive FVIIa-AT complex. As
further limitations, the population sample was limited and the polymorphisms for genetic
analysis were selected on the basis of a priori hypothesis (i.e. gene variants known
to influence the levels of apolipoproteins and plasma lipids). It should be noted
that a recent GWAS identifies only F7 promoter region and PROCR gene as loci associated
with circulating levels of FVIIa-AT.[18] Finally, we recognize the lack of some laboratory parameters, like other apolipoproteins
which are known to be involved in TRLs metabolism (e.g. ApoC-II and ApoA-V).
In summary, our results indicate a strong association between ApoC-III and FVIIa-AT,
thereby suggesting that an increased ApoC-III concentration may identify subjects
with a pro-thrombotic diathesis characterized by an enhanced TF-FVIIa interaction.
Our results should be confirmed by further studies, both investigating the underlying
molecular mechanisms and validating our findings in larger populations. Nonetheless,
they support the fascinating hypothesis of an additional and clinically relevant link
between plasma lipids and coagulation which may pave the way to new approaches in
the management of CVD.
What is known about this topic?
-
Plasma lipoproteins can stimulate coagulation cascade, with triglyceride-rich lipoproteins
(TRLs) being apparently the most efficient.
-
Tissue factor (TF) and activated factor VII (FVIIa) are involved in phospholipid interactions
which enhance their coagulant activity.
-
Activated factor VII–anti-thrombin complex (FVIIa-AT) in plasma may reflect tissue
factor (TF) exposure and TF-FVIIa interaction.
What does this paper add?
-
Apolipoprotein C-III (ApoC-III), a crucial player of TRLs metabolism, showed the strongest
correlation with FVIIa-AT among all plasma lipid parameters.
-
The APOC3-tagging polymorphism rs964184, linked by GWAS with cardiovascular diseases,
was consistently associated with both ApoC-III and FVIIa-AT plasma levels.
-
An increased ApoC-III concentration may identify subjects with a pro-thrombotic diathesis
characterized by an enhanced TF-FVIIa interaction.
